title: An analysis of original research contributions toward FDA-approved drugs.
abstract: Academic researchers shaped the landscape of drug discovery for nearly two centuries, and their efforts initiated programs for more than half of the US Food and Drug Administration (FDA)-approved new molecular entities (NMEs). During the first 50 years of the 20th century, contributions from industry-based discovery programs steadily increased, stabilizing near half of all first publications for NMEs. Although academia and industry have made similar contributions to the discovery of FDA-approved NMEs, there remains a substantial difference in the gap-to-approval; on average, industry NMEs are 12 years closer to market at the time of the first publication. As more drug discovery efforts shift from industry to academia, including high-throughput screening resources, academia could have an increasingly crucial role in drug discovery.
authors.affiliation: Yale Center for Molecular Discovery, West Haven, CT 06516, USA. Electronic address: eric.patridge@yale.edu.
authors.forename: Eric V
authors.initials: EV
authors.lastname: Patridge
authors.affiliation: Yale Center for Molecular Discovery, West Haven, CT 06516, USA.
authors.forename: Peter C
authors.initials: PC
authors.lastname: Gareiss
authors.affiliation: Washington University in St Louis, St Louis, MO 63110, USA.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kinch
authors.affiliation: Yale Center for Molecular Discovery, West Haven, CT 06516, USA.
authors.forename: Denton W
authors.initials: DW
authors.lastname: Hoyer
mesh_terms: D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D057166:High-Throughput Screening Assays / Q000639:trends; D006801:Humans; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration